Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, which has been discontinued following a company reorganization [2][3]. Summary by Relevant Sections Company Overview - Intellia Therapeutics, Inc. (NASDAQ: NTLA) is involved in developing treatments for genetic diseases, with a focus on viral-based editing technologies [2]. Allegations - The lawsuit claims that Intellia's management provided investors with optimistic timelines for the NTLA-3001 study, stating that the first patient would be dosed in the second half of 2024 [2]. - It is alleged that the company failed to disclose a significant decline in demand for viral-based editing methods, as non-viral delivery systems gained traction due to their cost-effectiveness and efficiency [2]. Company Actions - On January 9, 2025, Intellia announced a halt to all NTLA-3001 research and a workforce reduction of 27% in 2025, indicating a strategic shift in focus towards other pharmaceutical developments [2]. - Following this announcement, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to $10.20 per share on January 10, 2025 [2]. Class Action Details - Shareholders who purchased NTLA shares between July 30, 2024, and January 8, 2025, are encouraged to register for the class action lawsuit, with a deadline of April 14, 2025, to seek lead plaintiff status [3]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [3]. Legal Representation - The Gross Law Firm is leading the class action, emphasizing its commitment to protecting investors' rights against deceitful practices [4].

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 30, 2024, and January 8, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors impacted by the failure to disclose critical information regarding Intellia's Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [2] - Defendants allegedly misled investors by expressing confidence in the study's timeline, stating that the first patient would be dosed in the second half of 2024, while failing to disclose a decline in demand for viral-based editing methods [2] - The truth about the company's situation was revealed on January 9, 2025, when Intellia announced a halt to all NTLA-3001 research and a 27% workforce reduction, leading to a significant drop in stock price from $12.02 to $10.20 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 30, 2024, and January 8, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for Intellia investors who were impacted by the company's failure to disclose critical information regarding its Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [2] - Defendants allegedly misled investors by expressing confidence in the study's timeline, stating that the first patient would be dosed in the second half of 2024, while failing to reveal a significant decline in demand for viral-based editing methods [2] - On January 9, 2025, Intellia announced a reorganization, halting all NTLA-3001 research and reducing its workforce by 27%, which led to a significant drop in stock price from $12.02 on January 8, 2025, to $10.20 on January 10, 2025 [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4]

The collaboration with Regeneron for nex-z is a boost for Intellia as it provides the latter with resources to support the development of the candidate. NTLA's Another Candidate NTLA-2002 & Other Developments Intellia Therapeutics, Inc. (NTLA) is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis. Intellia has collaborated with Regeneron Pharmaceuticals (REGN) for the development ...

NEW YORK, March 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=139401&from=4 CLASS PE ...

NEW YORK, March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/intellia-therapeutics ...

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the viability and development of its gene editing therapy NTLA-3001, leading to significant stock price declines [4][5]. Company Overview - Intellia Therapeutics is a genome editing company focused on developing curative therapeutics [3]. Class Action Details - The class action lawsuit represents investors who purchased Intellia securities between July 30, 2024, and January 8, 2025, with a deadline for filing a lead plaintiff motion set for April 14, 2025 [1]. - The lawsuit alleges that Intellia's management made false statements about the reliability of NTLA-3001's development and failed to disclose critical information about the program's viability [4]. Allegations Against Intellia - The lawsuit claims that Intellia misrepresented the timelines and feasibility of NTLA-3001, asserting that the viral-based editing methods were costly and inefficient compared to non-viral alternatives [4]. - It is alleged that Intellia was not prepared to dose patients with NTLA-3001 or maintain its research and development efforts effectively [4]. - Following a company reorganization announcement on January 9, 2025, which included the discontinuation of NTLA-3001, Intellia's stock price dropped by over 15% [5].

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/intellia-therap ...

Intellia Therapeutics (NTLA) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational in vivo genome-editing candidate, Nexiguran ziclumeran (nex-z, also known as NTLA-2001), for a new indication.The regulatory body has now granted the RMAT designation to nex-z for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM).The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...